NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

April 3, 2026

Study Completion Date

May 18, 2026

Conditions

KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNon-Small Cell Lung CarcinomaNonsmall Cell Lung CancerColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsNeoplasms, Colorectal

Interventions

DRUG

JDQ443

KRAS G12C inhibitor, oral

DRUG

trametinib

MEK inhibitor, oral

DRUG

Ribociclib

CDK4/6 inhibitor, oral

BIOLOGICAL

cetuximab

EGFR inhibitor, intravenous

Trial Locations (13)

3000

Novartis Investigative Site, Leuven

10015

NYU School of Medicine, New York

20162

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

28050

Novartis Investigative Site, Madrid

33076

Novartis Investigative Site, Bordeaux

69373

Novartis Investigative Site, Lyon

79106

Novartis Investigative Site, Freiburg im Breisgau

168583

Novartis Investigative Site, Singapore

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

03080

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona